AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RCKT · NASDAQ · Biotechnology

Rocket Pharmaceuticals (RCKT)

Develops gene therapies for rare immune and cardiovascular disorders.

$3.43

After-hours close+0.08 (+2.24%)

At close$3.36(+2.60%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	2	2	0	0	0	0	0	0	2	0
Gross profit	0	0	−2	−2	0	0	0	0	0	0	−2	0
	65	63	65	71	69	63	64	71	52	44	46	47
Research & development	47	42	44	45	42	37	36	43	34	29	31	29
	19	22	21	27	27	25	28	25	18	15	17	17
Selling & marketing	0	0	−1	−1	0	0	0	0	0	0	0	0
General & administrative	19	22	22	27	27	25	28	25	18	15	17	17
Other expenses	0	0	0	0	0	0	0	3	0	0	−2	0
Operating income	−65	−63	−67	−74	−69	−63	−64	−71	−52	−44	−49	−47
	4	4	5	4	3	2	3	2	2	1	1	179
Interest income	4	4	6	5	3	3	4	3	2	6	1	0
Interest expense	0	0	0	0	0	0	0	0	0	3	0	0
Other non-operating income	−4	−4	−6	−5	−3	−3	−4	−3	−2	−5	−1	−179
Income before tax	−62	−60	−62	−70	−67	−60	−61	−69	−50	−43	−48	132
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	9
Net income from continuing operations	−62	−60	−62	−70	−67	−60	−61	−69	−50	−43	−48	123
Net income	−62	−60	−62	−70	−67	−60	−61	−69	−50	−43	−48	123
EPS, basic	−$0.75	−$0.64	−$0.66	−$0.74	−$0.71	−$0.62	−$0.56	−$0.62	−$0.45	−$0.38	−$0.42	$1.09
EPS, diluted	−$0.75	−$0.64	−$0.66	−$0.74	−$0.71	−$0.62	−$0.56	−$0.62	−$0.45	−$0.38	−$0.42	$1.08
Weighted average shares, basic	83	93	94	94	94	98	110	111	112	111	112	113
Weighted average shares, diluted	83	93	94	94	94	98	110	111	112	111	112	115
EBITDA	−60	−57	−59	−67	−64	−57	−58	−66	−47	−37	−45	137
Depreciation & amortization	2	2	2	2	2	2	3	3	3	2	2	4
EBIT	−61	−59	−62	−69	−66	−60	−61	−68	−50	−39	−47	132